Seaport Global analyst Mark Weintraub downgrades KB Home (NYSE:KBH) from Buy to Neutral.
Oppenheimer Maintains Outperform on Bionano Genomics, Lowers Price Target to $9
Oppenheimer analyst Francois Brisebois maintains Bionano Genomics (NASDAQ:BNGO) with a Outperform and lowers the price target from $12 to $9.